000284763 001__ 284763
000284763 005__ 20240229155055.0
000284763 0247_ $$2doi$$a10.3390/diagnostics13193043
000284763 0247_ $$2pmid$$apmid:37835787
000284763 0247_ $$2pmc$$apmc:PMC10572143
000284763 037__ $$aDKFZ-2023-02074
000284763 041__ $$aEnglish
000284763 082__ $$a610
000284763 1001_ $$0P:(DE-He78)b1b2f6c878545eac4cbd9729d8c10b7d$$aWankhede, Durgesh$$b0$$eFirst author$$udkfz
000284763 245__ $$aPrognostic Role of KRAS G12C Mutation in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
000284763 260__ $$aBasel$$bMDPI$$c2023
000284763 3367_ $$2DRIVER$$aarticle
000284763 3367_ $$2DataCite$$aOutput Types/Journal article
000284763 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1697800676_29654$$xReview Article
000284763 3367_ $$2BibTeX$$aARTICLE
000284763 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000284763 3367_ $$00$$2EndNote$$aJournal Article
000284763 500__ $$a#EA:C070#
000284763 520__ $$aKRAS G12C mutation (mKRAS G12C) is the most frequent KRAS point mutation in non-small cell lung cancer (NSCLC) and has been proven to be a predictive biomarker for direct KRAS G12C inhibitors in advanced solid cancers. We sought to determine the prognostic significance of mKRAS G12C in patients with NSCLC using the meta-analytic approach. A protocol is registered at the International Prospective Register for systematic reviews (CRD42022345868). PubMed, EMBASE, The Cochrane Library, and Clinicaltrials.gov.in were searched for prospective or retrospective studies reporting survival data for tumors with mKRAS G12C compared with either other KRAS mutations or wild-type KRAS (KRAS-WT). The hazard ratios (HRs) for overall survival (OS) or Disease-free survival (DFS) of tumors were pooled according to fixed or random-effects models. Sixteen studies enrolling 10,153 participants were included in the final analysis. mKRAS G12C tumors had poor OS [HR, 1.42; 95% CI, 1.10-1.84, p = 0.007] but similar DFS [HR 2.36, 95% CI 0.64-8.16] compared to KRAS-WT tumors. Compared to other KRAS mutations, mKRAS G12C tumors had poor DFS [HR, 1.49; 95% CI, 1.07-2.09, p < 0.0001] but similar OS [HR, 1.03; 95% CI, 0.84-1.26]. Compared to other KRAS mutations, high PD-L1 expression (>50%) [OR 1.37 95% CI 1.11-1.70, p = 0.004] was associated with mKRAS G12C tumors. mKRAS G12C is a promising prognostic factor for patients with NSCLC, negatively impacting survival. Prevailing significant heterogeneity and selection bias might reduce the validity of these findings. Concomitant high PD-L1 expression in these tumors opens doors for exciting therapeutic potential.
000284763 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000284763 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000284763 650_7 $$2Other$$aKRAS
000284763 650_7 $$2Other$$aKRAS G12C
000284763 650_7 $$2Other$$aNSCLC
000284763 650_7 $$2Other$$ameta-analysis
000284763 650_7 $$2Other$$anon-small cell lung cancer
000284763 650_7 $$2Other$$asystematic review
000284763 7001_ $$00000-0001-5446-6197$$aBontoux, Christophe$$b1
000284763 7001_ $$aGrover, Sandeep$$b2
000284763 7001_ $$00000-0003-0431-9353$$aHofman, Paul$$b3
000284763 773__ $$0PERI:(DE-600)2662336-5$$a10.3390/diagnostics13193043$$gVol. 13, no. 19, p. 3043 -$$n19$$p3043$$tDiagnostics$$v13$$x2075-4418$$y2023
000284763 909CO $$ooai:inrepo02.dkfz.de:284763$$pVDB
000284763 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b1b2f6c878545eac4cbd9729d8c10b7d$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000284763 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000284763 9141_ $$y2023
000284763 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-07-07T16:30:38Z
000284763 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-07-07T16:30:38Z
000284763 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-07-07T16:30:38Z
000284763 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2023-07-07T16:30:38Z
000284763 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-31
000284763 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-31
000284763 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-31
000284763 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-31
000284763 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bDIAGNOSTICS : 2022$$d2023-10-26
000284763 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000284763 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000284763 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
000284763 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-26
000284763 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-26
000284763 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000284763 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000284763 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-26
000284763 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-26
000284763 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000284763 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000284763 980__ $$ajournal
000284763 980__ $$aVDB
000284763 980__ $$aI:(DE-He78)C070-20160331
000284763 980__ $$aUNRESTRICTED